Related Experiment Video
Updated: Mar 21, 2026

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
Published on: August 20, 2019
Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Vittoriano Della Corte, Antonino Tuttolomondo1, Rosaria Pecoraro
1Dipartimento Biomedico di Medicina Interna e Specialistica, Facoltà di Medicina e Chirurgia, Università degli Studi di Palermo, Italy, Piazza delle Cliniche n.2, 90127 Palermo, Italy. bruno.tuttolomondo@unipa.it.
Insights
Arterial stiffness, endothelial dysfunction, and inflammatory markers are key indicators of cardiovascular disease risk. Assessing these markers together provides a comprehensive view for better therapeutic strategies.
Area of Science:
- Cardiovascular Medicine
- Vascular Biology
- Biomarker Research
Background:
- Atherosclerosis and cardiovascular events are linked to arterial stiffness, endothelial dysfunction, and immunoinflammatory markers.
- Arterial stiffness, assessed via pulse wave velocity (PWV) and augmentation index (AIx), predicts cardiovascular morbidity and mortality.
- Endothelial dysfunction impairs vascular homeostasis, promoting vasoconstriction, thrombosis, and atherosclerosis, measurable by flow-mediated dilation (FMD), L-FMC, and reactive hyperemia index (RHI).
Purpose of the Study:
- To review the role of arterial stiffness, endothelial dysfunction, and immunoinflammatory markers as surrogate endpoints in cardiovascular disease.
- To assess the correlations between these vascular markers.
- To evaluate the therapeutic perspectives offered by these markers.
Main Methods:
- Review of existing literature on arterial stiffness, endothelial dysfunction, and inflammatory markers.
- Analysis of non-invasive techniques for assessing arterial stiffness (e.g., PWV, AIx) and endothelial function (e.g., FMD, L-FMC, RHI).
- Examination of the role of inflammatory biomarkers, such as C-reactive protein (CRP), in atherogenesis.
Main Results:
- Arterial stiffness is an independent predictor of cardiovascular events in various populations.
- Loss of endothelial function contributes to a pro-atherosclerotic vascular phenotype.
- C-reactive protein (CRP) is a promising inflammatory biomarker for predicting cardiovascular events.
Conclusions:
- Arterial stiffness, endothelial dysfunction, and immunoinflammatory markers are crucial surrogate endpoints in cardiovascular disease.
- These markers are complementary, offering different insights into cardiovascular pathology.
- Understanding and assessing these markers can guide therapeutic strategies for cardiovascular disease prevention and management.
Abstract:
In the last decades, many factors thought to be associated with the atherosclerotic process and cardiovascular events have been studied, and some of these have been shown to correlate with clinical outcome, such as arterial stiffness, endothelial dysfunction and immunoinflammatory markers. Arterial stiffness is an important surrogate marker that describes the capability of an artery to expand and contract in response to pressure changes. It can be assessed with different techniques, such as the evaluation of PWV and AIx. It is related to central systolic pressure and it is an independent predictor of cardiovascular morbidity and mortality in hypertensive patients, type 2 diabetes, end-stage renal disease and in elderly populations. The endothelium has emerged as the key regulator of vascular homeostasis, in fact, it has not merely a barrier function but also acts as an active signal transducer for circulating influences that modify the vessel wall phenotype. When its function is lost, it predisposes the vasculature to vasoconstriction, leukocyte adherence, platelet activation, thrombosis and atherosclerosis. Non-invasive methods were developed to evaluate endothelial function, such as the assesment of FMD, L-FMC and RHI. Moreover in the last years, a large number of studies have clarified the role of inflammation and the underlying cellular and molecular mechanisms that contribute to atherogenesis. For clinical purposes, the most promising inflammatory biomarker appears to be CRP and a variety of population-based studies have showed that baseline CRP levels predict future cardiovascular events. Each of the markers listed above has its importance from the pathophysiological and clinical point of view, and those can also be good therapeutic targets. However, it must be stressed that assessments of these vascular markers are not mutually exclusive, but rather complementary and those can offer different views of the same pathology. The purpose of this review is to analyze the role of arterial stiffness, endothelial dysfunction and immunoinflammatory markers as surrogate endpoint, assessing the correlations between these markers and evaluating the therapeutic perspectives that these offer.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Atherosclerosis I: Introduction
Peripheral Artery Disease III: Interprofessional Care
Coronary Artery Disease II: Pathophysiology
Peripheral Artery Disease I: Introduction

